LUNG

1.42

3.40% -0.05

Vorhandelsmarkt: 1.43 0.01 +0.70%

Pulmonx Corp (LUNG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.47

Offen:

$1.47

24-Stunden-Volumen:

344.16K

Relative Volume:

0.73

Marktkapitalisierung:

$59.98M

Einnahmen:

$90.50M

Nettoeinkommen (Verlust:

$-54.00M

KGV:

-1.068

EPS:

-1.3296

Netto-Cashflow:

$-32.90M

1W Leistung:

-1.39%

1M Leistung:

+4.41%

6M Leistung:

-14.97%

1J Leistung:

-68.58%

1-Tages-Spanne:

$1.40

$1.515

1-Wochen-Bereich:

$1.40

$1.60

52-Wochen-Spanne:

$1.13

$5.459

Pulmonx Corp Stock (LUNG) Company Profile

Firmenname

Pulmonx Corp

Sektor

Healthcare (1114)

Branche

Medical Devices (142)

Telefon

650-364-0400

Adresse

700 CHESAPEAKE DRIVE, REDWOOD CITY

Mitarbeiter

296

Twitter

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

LUNG's Discussions on Twitter

Compare LUNG vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LUNG Pulmonx Corp	1.42	62.09M	90.50M	-54.00M	-32.90M	-1.3296
ABT Abbott Laboratories	96.00	168.22B	45.13B	6.28B	7.40B	3.5895
SYK Stryker Corp	338.34	131.49B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	85.00	110.66B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	60.99	95.46B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	81.44	46.69B	6.07B	1.06B	1.34B	1.8063

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-31	Herabstufung	Piper Sandler	Overweight → Neutral
2025-03-10	Eingeleitet	D. Boral Capital	Buy
2024-12-11	Herabstufung	Citigroup	Buy → Neutral
2024-06-04	Eingeleitet	Lake Street	Buy
2024-02-23	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-09-05	Eingeleitet	Craig Hallum	Buy
2023-02-27	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-01-03	Herabstufung	BofA Securities	Neutral → Underperform
2022-12-12	Hochstufung	Citigroup	Neutral → Buy
2022-07-11	Herabstufung	Citigroup	Buy → Neutral
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2021-12-08	Hochstufung	Piper Sandler	Neutral → Overweight
2021-04-01	Eingeleitet	Citigroup	Buy
2021-03-25	Eingeleitet	Piper Sandler	Neutral
2021-03-10	Hochstufung	BofA Securities	Neutral → Buy
2021-01-04	Herabstufung	BofA Securities	Buy → Neutral
2020-10-26	Eingeleitet	BofA Securities	Buy
2020-10-26	Eingeleitet	Canaccord Genuity	Buy
2020-10-26	Eingeleitet	Morgan Stanley	Equal-Weight
2020-10-26	Eingeleitet	Stifel	Buy
2020-10-26	Eingeleitet	Wells Fargo	Equal Weight

Alle ansehen

Pulmonx Corp Aktie (LUNG) Neueste Nachrichten

Apr 19, 2026

How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk - Yahoo Finance

Apr 19, 2026

Apr 15, 2026

Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan

Apr 15, 2026

Apr 14, 2026

LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill

Apr 14, 2026

Apr 13, 2026

Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS

Apr 13, 2026

Apr 05, 2026

Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm

Apr 05, 2026

Apr 04, 2026

How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance

Apr 04, 2026

Apr 03, 2026

Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus

Apr 03, 2026

Apr 02, 2026

Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com

Apr 02, 2026

Mar 30, 2026

Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan

Mar 27, 2026

Mar 22, 2026

If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan

Mar 22, 2026

Mar 21, 2026

How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance

Mar 21, 2026

Mar 15, 2026

LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 15, 2026

Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS

Mar 15, 2026

Mar 14, 2026

Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn

Mar 14, 2026

Mar 11, 2026

Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart

Mar 11, 2026

LUNG Technical Analysis & ETF Price Forecast - Intellectia AI

Mar 11, 2026

Mar 10, 2026

Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable - Stock Titan

Mar 10, 2026

Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView

Mar 10, 2026

Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative

Mar 10, 2026

Mar 09, 2026

Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan

Mar 09, 2026

Mar 06, 2026

Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 06, 2026

Mar 05, 2026

Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView

Mar 05, 2026